Navigation Links
MIT works toward novel therapeutic device
Date:10/22/2007

CAMBRIDGE, Mass.-MIT and University of Rochester researchers report important advances toward a therapeutic device that has the potential to capture cells as they flow through the blood stream and treat them. Among other applications, such a device could zapp cancer cells spreading to other tissues, or signal stem cells to differentiate.

Their concept leverages cell rolling, a biological process that slows cells down as they flow through blood vessels. As the cells slow, they adhere to the vessel walls and roll, allowing them to sense signals from nearby tissues that may be calling them to work. Immune cells, for example, can be slowed and summoned to battle an infection.

Through mimicking a process involved in many important physiological and pathological events, we envision a device that can be used to selectively provide signals to cells traveling through the bloodstream, said Jeffrey M. Karp of the Harvard-MIT Division of Health Sciences and Technology. This technology has applications in cancer and stem cell therapies and could be used for diagnostics of a number of diseases.

The team, led by Karp, started with technology to induce cell rolling for research. With an implantable therapeutic device in mind, they improved that cell rolling technology to make it safe, more stable and longer lasting.

The improvements are described in the October 20 online issue of the journal Langmuir, published by the American Chemical Society.

In the body, P-selectin and other selectin proteins regulate cell rolling in blood vessels. When P-selectin is present on a vessel's inner wall, cells that are sensitive to it will stick to that patch and begin to roll across it.

To induce rolling in the laboratory, the original technology weakly adheres P-selectin to a glass surface and flows cells across it. This surface treatment remains stable for several hours then breaks down. While this method is useful for experiments, it's not good for long-term stability, said Karp. An implantable device needs a coating that lasts weeks or even months so that patients won't need to come in frequently for replacements.

To improve the technology, the team experimented with several chemical methods to immobilize P-selectin on a glass surface. They identified a polyethelene glycol (PEG) coating that strongly bonded to P-selectin. This coating is also non-fouling, meaning it does not react with or accumulate other proteins, so it is potentially safe for use in an implant.

P-selectin remains stable on this coating for longer than the original technology. In tests with microspheres coated with a molecule that interacts with P-selectin, these spheres slowed down significantly as they flowed over the surface coated with layers of PEG and P-selectin. The effect was stable past four weeks, the longest the devices have been tested.

To validate that this technology works with cells that are sensitive to P-selectin, the team flowed neutrophils (white blood cells) across the coated surface. They too slowed and rolled on surfaces treated with the new coating, and the effect again lasted for at least four weeks.

The next step is translating these results to animal studies and using the technology to slow and capture stem cells and cancer cells circulating in the blood stream.

Ultimately CellTraffix, Inc., a sponsor of this technology and its licensee, wants to apply the technique to a device that is either implanted into the blood stream or appended as a shunt. In addition to PEG and selectin molecules, the device would also include a therapeutic agent. Such an agent would interact only with certain cells for a specific purpose.

According to University of Rochester biomedical engineering professor Michael King, who developed the concept for adhesive capture and reprogramming of cells, the device could, for example, slow down metastatic, or spreading, cancer cells and kill them.


'/>"/>

Contact: Elizabeth Thomson
thomson@mit.edu
617-258-5402
Massachusetts Institute of Technology
Source:Eurekalert

Related medicine news :

1. Fireworks can spell death for asthmatic children
2. How a mans mind really works
3. Drug Combo Works Better for children with ADHD, Tics
4. How brain works
5. Meditation Works Medically
6. A first in Liver Transplant in India – Networking works wel
7. Warts: Spanner in Lovers Works!
8. Shot Supply: Reduced Dosage of Seasonal flu Vaccine, Works!
9. Subliminal Advertising works
10. De-addiction Drug Works For Alcoholics Too
11. Vagal Nerve Stimulation Works To Treat Severe Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Providing for ... understand the estate planning process, or where to even begin. “Now more than ever ... you are to properly protect yourself and your family,” said attorney Lisa Edgar Dickman, ...
(Date:4/21/2017)... ... April 21, 2017 , ... Westside Dental Associates ... dental care since 1985. After thirty-two years, Dr. Latner has become one of the ... my numerous clients over the years with all their dental needs,” said Dr. Latner, ...
(Date:4/21/2017)... ... ... Each year, everyone is urged to give back to the earth on April ... a better future. However, supporting the environment should be an everyday practice. , ... to five times more polluted than outdoor air, reports the Environmental Protection Agency -- ...
(Date:4/21/2017)... Houston, Texas (PRWEB) , ... April 21, 2017 ... ... repeal…. sound familiar? These are five common elements between the Obamacare program ... feral hog control program which uses Warfarin poison to kill hogs. , ...
(Date:4/21/2017)... ... April 21, 2017 , ... Indiana ... significant bandwidth upgrade infrastructure service to Tele-Media Solutions. IFN is delivering Multi-Gigabit ... IFN’s consortium member-owners, Tele-Media Solution’s protect transport with 3GB Dual Access Internet access ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Eyevensys, a private biotechnology company developing its ... that enables the safe, local, sustained production of therapeutic ... of ophthalmic diseases, announces it has received approval from ... to advance its technology into clinical development. ... The EyeCET platform uses ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
Breaking Medicine Technology: